Home>>Signaling Pathways>> Membrane Transporter/Ion Channel>> NMDA Receptor>>DL-AP5

DL-AP5 (Synonyms: DL-2-Amino-5-Phosphonovaleric acid,2-APV)

Catalog No.GC17206

A NMDA antagonist

Products are for research use only. Not for human use. We do not sell to patients.

DL-AP5 Chemical Structure

Cas No.: 76326-31-3

Size Price Stock Qty
5mg
$63.00
In stock
10mg
$99.00
In stock
25mg
$232.00
In stock
50mg
$431.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

DL-AP5 is the racemic version of the selective N-methyl-D-aspartate (NMDA) receptor antagonist, D-AP5 .[1] Whereas D-AP5 is the active (−)-stereoisomer that competitively inhibits the glutamate binding site of NMDA receptors (Kd = 1.4 μM), the (+)-isomer (L-AP5) demonstrates considerably less potent NMDA receptor antagonist activity.1 AP5 has been widely used to study the activity of NMDA receptors particularly in regard to researching synaptic plasticity, learning, and memory.[2]

Reference:
[1]. Evans, R.H., Francis, A.A., Jones, A.W., et al. The effects of a series of ω-phosphonic α-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations. Br. J. Pharmacol. 75(1), 65-75 (1982).
[2]. Morris, R.J. Synaptic plasticity and learning: Selective impairment of learning rats and blockade of long-term potentiation in vivo by the N-methyl-D-aspartate receptor antagonist AP5. J. Neurosci. 9(9), 3040-3057 (1989).

Reviews

Review for DL-AP5

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DL-AP5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.